---
search:
  boost: 3
---

 # Growth Hormone

This is a subcategory of Endocrine Agents.

## Decision Trees

- [Endocrine - Growth Hormone- Non-Preferred Agents - Humatrope, Nutropin, Omnitrope, Saizen, Serostim, Skytrofa, Zomacton](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBURFdFUkQ4Q0lTM0FYVFU1QjdRNTg5QzI4SSQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [Endocrine - Growth Hormone- Preferred Agents - Genotropin, Norditropin](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUNDQ0NDBBT1JPRTZLTDdWM0RGUFRIN1JaOSQlQCN0PWcu){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred                 | Generic Name | Quantity | Time (Days) |
| :------------------------ | :----------- | :------: | :---------: |
| Genotropin <sup>PA</sup>  |              |          |             |
| Norditropin <sup>PA</sup> |              |          |             |

### Non-Preferred

| Non-Preferred | Generic Name | Quantity | Time (Days) |
| :------------ | :----------- | :------: | :---------: |
| Humatrope     |              |          |             |
| Nutropin      |              |          |             |
| Omnitrope     |              |          |             |
| Saizen        |              |          |             |
| Serostim      |              |          |             |
| Skytrofa      |              |          |             |
| Zomacton      |              |          |             |

## Authorizations

**Length of Authorizations**: Initial: 180 days; Subsequent: 365 days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Clinical PA

Clincial PA Criteria

**Pediatric Approvals (under 18 years of age):**

- Must be treated and followed by a pediatric endocrinologist, nephrologist, clinical geneticist, endocrinologist, or gastroenterologist (or as appropriate for diagnosis)
- Must provide documentation to justify criteria being met, including height, weight, bone age (children), date and results of most current x-ray, stimulus test results, IGF-1 levels, and a growth chart (children)
- Must not being used in combination with another somatropin agent

**Adult Approvals (18 years of age or older):**

- Must be treated and following by an endocrinologist
- Must provide documentation of growth hormone deficiency by means of a negative response to an appropriate stimulation test (clonidine test is not acceptable for adults)
- Must provide documentation of baseline evaluation of the following clinical indicators: (1) insulin-like growth factor (IGF-1); (2) fasting lipid profile; (3) BUN; (4) fasting glucose; (5) electrolytic levels; (6) evaluation of any new osteoarthritis and joint pain; (7) bone density test
- Must have had other hormonal deficiencies addressed with adequate replacement therapy

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least ^^90 days^^ with at least ^^one preferred^^ drug
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patientâ€™s clinical response to treatment and ongoingcsafety monitoring (i.e., height, weight gain, improved body composition) </br>
For adults: must provide documentation by endocrinologist that discontinuing agent would have a detrimental effect on body composition or other metabolic parameters

## Links

[Criteria](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701+UPDL+Criteria+_v1_FINAL.approved.pdf#page=59){ :target="_blank" rel="noopener"} </br>
[Preferred Drug List](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701_UPDL_FINAL_ODM.approved.v2.pdf#page=22){ :target="_blank" rel="noopener"} </br>
[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
